Arabic Arabic English English French French German German
dark

Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval

While the drug showed significant improvement in patients on a 200mg daily dose of filgotinib, it may not be promoted in the states any time soon. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

‘Wasfaty’ Service Activated in King Saud Medical City

Next Post

Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary

Related Posts
Total
0
Share